Loading...

Member Profile

Since its establishment in May 2000, microbio has been adhering to the concept of active innovation, focusing on the research and development of high-end products for new medicines and medical care, and gradually forming a biotechnology enterprise group with “innovation” as its core. In-depth development in new drug research and development, organic agriculture and biotechnology venture capital. While achieving corporate development and enhancing shareholders’ rights, we also fulfill our corporate social responsibility and care for our lives.

In terms of new drug research and development, Chemo young and Herbiron have obtained the new drug certificates approved by the Ministry of Health and Welfare, and have successfully developed a variety of microbial pharmaceutical technology platforms, and have repeatedly made major breakthroughs in the field of biotechnology. The Microbio has received many awards and professional awards such as Biomedical Quality Award and Biomedical Innovation Award. At the same time, Microbio continues to uphold professional and rigorous R&D management, combined with the first-class R&D team, to develop high-quality medical and health care products, including Tien Chun Boo, top quality enzyme drinks and Lee Herb series products and other patented leading products.


Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2000 Established Microbio Co., Ltd.
   2001 Longtan Plant was established and passed the GMP certification
   2004 Microbio Co., Ltd. was established
   2004 Established Taiwan’s first “New Drug Research and Development Center
   2006 Microbio’s stock has been officially listed on over the counter market (4128)
   2011 MS-20 (Chemo young) obtained the first certificate of oral solution for cancer new drug.
   2013 Herbiron obtained the first compound herbs new drug certificate
   2016 Joint development of the Pingtung County Nanjhou Township with ONENESS to establish PIC/S GMP Pharmaceutical Factory and Sightseeing Pharmaceutical Factory Park
   2020 MSCI added Microbio Co., to Global Small Cap Indexes
   2021 Announce the subsidiay Microbio (Shanghai) receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (ON101)
   2023 Annouced on behalf of Microbio (Shanghai) that FESPIXON, the new drug in treating DFUs has been approved as Class 1.1 natural new drug by China NMPA
   2024 Microbio (Shanghai) and Oneness have entered into an exclusive agreement of Fespixon commercialization with China Resources Double Crane Pharmaceutical Co., Ltd.
   2024 Symbiota exclusively developed by Microbio Co., Ltd. achieves an Independent/Self-affirmed GRAS conclusion according to the U.S. FDA regulations.